human | Q5 |
P213 | ISNI | 0000000387807351 |
P496 | ORCID iD | 0000-0002-9804-5340 |
P7293 | PLWABN ID | 9810607130005606 |
P2038 | ResearchGate profile ID | Bo_Ahren |
P214 | VIAF ID | 315221734 |
P27 | country of citizenship | Sweden | Q34 |
P108 | employer | Lund University | Q218506 |
P22 | father | Per-Olov Ahrén | Q5544511 |
P735 | given name | Bo | Q1234223 |
Bo | Q1234223 | ||
P106 | occupation | physician | Q39631 |
P39 | position held | board member | Q2824523 |
P21 | sex or gender | male | Q6581097 |
Q58448791 | 1,5-Anhydro-d-fructose increases glucose tolerance by increasing glucagon-like peptide-1 and insulin in mice |
Q57920219 | 35th Annual Meeting of the European Association for the Study of Diabetes |
Q56883844 | 35th Annual Meeting of the European Association for the Study of Diabetes : Brussels, Belgium, 28 September-2 October 1999 |
Q56836084 | 40 EASD Annual Meeting of the European Association for the Study of Diabetes : Munich, Germany, 5-9 September 2004 |
Q30997105 | A 90-day toxicological evaluation of 1,5-anhydro-d-fructose in Sprague-Dawley rats |
Q28307231 | A Palaeolithic diet improves glucose tolerance more than a Mediterranean-like diet in individuals with ischaemic heart disease |
Q21245074 | A Paleolithic diet confers higher insulin sensitivity, lower C-reactive protein and lower blood pressure than a cereal-based diet in domestic pigs |
Q67534322 | A new dextran 40-based solution for liver preservation |
Q46937429 | A novel approach to assess insulin sensitivity reveals no increased insulin sensitivity in mice with a dominant-negative mutant hepatocyte nuclear factor-1alpha |
Q24621806 | A paleolithic diet is more satiating per calorie than a mediterranean-like diet in individuals with ischemic heart disease |
Q71518718 | A role for islet peptide YY in the regulation of insulin secretion |
Q58329818 | A strong association between biologically active testosterone and leptin in non-obese men and women is lost with increasing (central) adiposity |
Q74352496 | Abnormal cytokine and adrenocortical hormone regulation in myotonic dystrophy |
Q43913459 | Abnormal release of incretins and cortisol after oral glucose in subjects with insulin-resistant myotonic dystrophy |
Q68019052 | Acetic acid-induced colitis in the rat: a reproducible experimental model for acute ulcerative colitis |
Q73303080 | Activation of autonomic nerves and the adrenal medulla contributes to increased glucagon secretion during moderate insulin-induced hypoglycemia in women |
Q73807086 | Acylation stimulating protein stimulates insulin secretion |
Q53550245 | Adrenal incidentaloma - follow-up results from a Swedish prospective study. |
Q42446036 | Adrenergic innervation of pancreatic islets and modulation of insulin secretion by the sympatho-adrenal system |
Q71507388 | Adrenomedullin: localization in the gastrointestinal tract and effects on insulin secretion |
Q51321430 | Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: a comparison of adding albiglutide, a weekly GLP-1 receptor agonist, versus thrice-daily prandial insulin lispro. |
Q44746434 | Aged transgenic mice with increased glucocorticoid sensitivity in pancreatic beta-cells develop diabetes |
Q21256397 | Agrarian diet and diseases of affluence--do evolutionary novel dietary lectins cause leptin resistance? |
Q50207588 | Alain Ktorza, PhD. |
Q40296997 | Albiglutide for the treatment of type 2 diabetes mellitus: An integrated safety analysis of the HARMONY phase 3 trials |
Q34559941 | Alpha 1- and alpha 2-adrenoceptor activation increases plasma glucagon levels in the mouse |
Q34560507 | Alpha cell function in health and disease: influence of glucagon-like peptide-1. |
Q69914209 | Alpha-adrenoceptor blockade by phentolamine inhibits beta-adrenergically and cholinergically induced glucagon secretion in the mouse |
Q44517923 | Alteration of the counterregulatory responses to insulin-induced hypoglycemia and of cognitive function after massive weight reduction in severely obese subjects |
Q42516520 | Altered beta-cell distribution of pdx-1 and GLUT-2 after a short-term challenge with a high-fat diet in C57BL/6J mice |
Q46136142 | Altered glucose tolerance in women with deliberate self-harm |
Q50988559 | Androgen activity as a risk factor for impaired glucose tolerance in postmenopausal women |
Q44122845 | Anti-diabetogenic effect of the human amylin analogue, pramlintide, in Type 1 diabetes is not mediated by GLP-1. |
Q73555568 | Antidiabetogenic action of cholecystokinin-8 in type 2 diabetes |
Q43674711 | Antidiabetogenic action of glucagon-like peptide-1 related to administration relative to meal intake in subjects with type 2 diabetes |
Q45306841 | Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus |
Q83226453 | Are sulfonylureas less desirable than DPP-4 inhibitors as add-on to metformin in the treatment of type 2 diabetes? |
Q82286447 | Arterial gastroduodenal infusion of cholecystokinin-33 stimulates the exocrine pancreatic enzyme release via an enteropancreatic reflex, without affecting the endocrine insulin secretion in pigs |
Q36218117 | Assessment of insulin secretion in relation to insulin resistance |
Q46815300 | Autonomic control of pancreatic polypeptide and glucagon secretion during neuroglucopenia and hypoglycemia in mice |
Q35080966 | Autonomic mechanism and defects in the glucagon response to insulin-induced hypoglycaemia |
Q53762233 | Autonomic mediation of glucagon secretion during hypoglycemia: implications for impaired alpha-cell responses in type 1 diabetes. |
Q51706573 | Autonomic neuropathy is associated with impaired pancreatic polypeptide and neuropeptide Y responses to insulin-induced hypoglycaemia in Type I diabetic patients. |
Q26827955 | Avoiding hypoglycemia: a key to success for glucose-lowering therapy in type 2 diabetes |
Q40518029 | Basic toxicology and metabolism studies of 1,5-anhydro-D-fructose using bacteria, cultured mammalian cells, and rodents |
Q24654138 | Beneficial effects of a Paleolithic diet on cardiovascular risk factors in type 2 diabetes: a randomized cross-over pilot study |
Q43542656 | Beta cell adaptation to dexamethasone-induced insulin resistance in rats involves increased glucose responsiveness but not glucose effectiveness |
Q33223590 | Beta-cell expression of a dominant-negative HNF-1alpha compromises the ability of inhibition of dipeptidyl peptidase-4 to elicit a long-term augmentation of insulin secretion in mice |
Q31131767 | Beta-cell-targeted expression of a dominant-negative mutant of hepatocyte nuclear factor-1alpha in mice: diabetes model with beta-cell dysfunction partially rescued by nonglucose secretagogues |
Q28594896 | Beta-cell-targeted overexpression of phosphodiesterase 3B in mice causes impaired insulin secretion, glucose intolerance, and deranged islet morphology |
Q46915411 | Binding and the effect of the red kidney bean lectin, phytohaemagglutinin, in the gastrointestinal tract of suckling rats |
Q43533303 | Biochemical determination of islet lysosomal enzyme activities following crinophagy-stimulating treatment with diazoxide in mice. |
Q72074590 | Blockade of galanin-induced inhibition of insulin secretion from isolated mouse islets by the non-methionine containing antagonist M35 |
Q71458211 | Blockade of muscarinic transmission increases the frequency of diabetes after low-dose alloxan challenge in the mouse |
Q39681233 | Body adiposity, insulin, and leptin in subgroups of Peruvian Amerindians |
Q80449927 | Body fat related to daily physical activity and insulin concentrations in non-diabetic children |
Q38336901 | Both leptin and leptin-receptor are essential for apolipoprotein M expression in vivo |
Q45147939 | Bovine growth hormone transgenic mice are resistant to diet-induced obesity but develop hyperphagia, dyslipidemia, and diabetes on a high-fat diet. |
Q38354850 | Bovine growth hormone-transgenic mice have major alterations in hepatic expression of metabolic genes |
Q51685119 | CART is overexpressed in human type 2 diabetic islets and inhibits glucagon secretion and increases insulin secretion. |
Q33216230 | CART knock out mice have impaired insulin secretion and glucose intolerance, altered beta cell morphology and increased body weight |
Q40983021 | CCK receptor subtype in insulin-producing cells: a combined functional and in situ hybridization study in rat islets and a rat insulinoma cell line |
Q68011395 | CCK-8-stimulated insulin secretion in vivo is mediated by CCKA receptors |
Q45060384 | CCKA receptor antagonism inhibits mechanisms underlying CCK-8-stimulated insulin release in isolated rat islets |
Q37602697 | Calcitonin gene-related peptide (CGRP) and amylin and the endocrine pancreas. |
Q43531338 | Calcitonin gene-related peptide inhibits insulin secretion studies on ion fluxes and cyclic AMP in isolated rat islets |
Q42521611 | Calcitonin gene-related peptide: occurrence in pancreatic islets in the mouse and the rat and inhibition of insulin secretion in the mouse |
Q57226862 | Calcitonin, calcitonin gene-related peptide, and gastrin-releasing peptide in familial thyroid medullary carcinoma |
Q69738590 | Calcium stimulates the release of calcitonin gene-related peptide from the canine thyroid |
Q51601381 | Capacity to secrete islet hormones after subtotal pancreatectomy for pancreatic cancer. |
Q74578914 | Capsaicin-induced sensory denervation increases glucose elimination in rodents |
Q51480280 | Capsaicin-sensitive sensory fibers in the islets of Langerhans contribute to defective insulin secretion in Zucker diabetic rat, an animal model for some aspects of human type 2 diabetes. |
Q43542662 | Carbachol restores insulin release in diabetic GK rat islets by mechanisms largely involving hydrolysis of diacylglycerol and direct interaction with the exocytotic machinery |
Q48094566 | Cerebrospinal fluid insulin during non-neurological surgery |
Q33751433 | Changes in prandial glucagon levels after a 2-year treatment with vildagliptin or glimepiride in patients with type 2 diabetes inadequately controlled with metformin monotherapy |
Q44599743 | Characterization of GLP-1 effects on beta-cell function after meal ingestion in humans |
Q70193660 | Cholecystokinin (CCK)-33 stimulates insulin secretion from the perfused rat pancreas: studies on the structure-activity relationship |
Q69920267 | Cholecystokinin (CCK)-4 and CCK-8 stimulate islet hormone secretion in vivo in the pig |
Q35692812 | Cholecystokinin and the regulation of insulin secretion |
Q68147839 | Cholecystokinin-33 potentiates and vasoactive intestinal polypeptide inhibits gastric inhibitory polypeptide--induced insulin secretion in the perfused rat pancreas |
Q44531334 | Cholecystokinin-stimulated insulin secretion and protein kinase C in rat pancreatic islets |
Q36616404 | Cholinergic regulation of the endocrine pancreas |
Q42488484 | Chronic glucokinase activation reduces glycaemia and improves glucose tolerance in high-fat diet fed mice |
Q43542496 | Circulating IGF binding protein-1 is inversely associated with leptin in non-obese men and obese postmenopausal women |
Q45387158 | Clinical characteristics, treatment and survival in patients with pancreatic tumors causing hormonal syndromes |
Q37825941 | Clinical evidence and mechanistic basis for vildagliptin's action when added to metformin |
Q38083641 | Clinical evidence and mechanistic basis for vildagliptin's effect in combination with insulin |
Q37160675 | Clinical measures of islet function: usefulness to characterize defects in diabetes |
Q37595942 | Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin--diabetes control and potential adverse events |
Q45296755 | Comparative evaluation of simple insulin sensitivity methods based on the oral glucose tolerance test |
Q54294726 | Comparison of effects of neuropeptide Y and norepinephrine on insulin secretion and vascular resistance in perfused rat pancreas. |
Q51314476 | Conditional glucagon receptor overexpression has multi-faceted consequences for beta-cell function. |
Q97682155 | Consequences on islet and incretin hormone responses to dinner by omission of lunch in healthy men |
Q67850206 | Contribution of adrenergic nerves and the adrenals to 2-Deoxy-D-glucose-induced insulin and glucagon secretion in the mouse |
Q67705277 | Contribution of galanin to stress-induced impairment of insulin secretion in swimming mice |
Q72681724 | Contribution of liver nerves, glucagon, and adrenaline to the glycaemic response to exercise in rats |
Q43733884 | Contribution to glucose tolerance of insulin-independent vs. insulin-dependent mechanisms in mice |
Q82790982 | Contributions from the first SICOD (Swedish-Italian Cooperation on Diabetes Research) meeting, Stockholm, Sweden, October 2004 |
Q28293086 | Correlation of apolipoprotein M with leptin and cholesterol in normal and obese subjects |
Q61774897 | Cortisol axis abnormalities early after stroke - relationships to cytokines and leptin |
Q39027188 | Creative use of novel glucose-lowering drugs for type 2 diabetes: where will we head in the next 50 years? |
Q69499448 | Cysteamine and the endocrine pancreas: immunocytochemical, immunochemical, and functional aspects |
Q52536208 | Cytosolic Ca2+ oscillations by gastrin releasing peptide in single HIT-T15 cells. |
Q91638366 | DPP-4 Inhibition and the Path to Clinical Proof |
Q27028127 | DPP-4 inhibition and islet function |
Q86689215 | DPP-4 inhibition contributes to the prevention of hypoglycaemia through a GIP-glucagon counterregulatory axis in mice |
Q51754123 | DPP-4 inhibition improves glucose tolerance and increases insulin and GLP-1 responses to gastric glucose in association with normalized islet topography in mice with beta-cell-specific overexpression of human islet amyloid polypeptide. |
Q33308406 | DPP-4 inhibitors |
Q50152436 | DPP-4 is expressed in human pancreatic beta cells and its direct inhibition improves beta cell function and survival in type 2 diabetes |
Q50889725 | Deciphering the Hypoglycemic Glucagon Response: Development of a Graded Hyperinsulinemic Hypoglycemic Clamp Technique in Female Mice |
Q51292778 | Decreased insulin secretion and glucose clearance in exocrine pancreas-insufficient pigs. |
Q86963296 | Defective insulin secretion by chronic glucagon receptor activation in glucose intolerant mice |
Q42135711 | Dependence on extracellular Ca2+ for the effects of cholecystokinin-8 in rat pancreatic islets |
Q44485081 | Determinants of serum triglycerides and high-density lipoprotein cholesterol in traditional Trobriand Islanders: the Kitava Study |
Q43593468 | Determination of thyroxine release in vivo: a simple, specific and sensitive method in mice |
Q41115408 | Dexamethasone induces neuropeptide Y (NPY) expression and impairs insulin release in the insulin-producing cell line RINm5F. Release of NPY and insulin through different pathways |
Q71580039 | Dexamethasone-induced neuropeptide Y expression in rat islet endocrine cells. Rapid reversibility and partial prevention by insulin |
Q44381337 | Diabetes and impaired fasting glycemia in a rural population of Bangladesh |
Q36930635 | Diazepam binding inhibitor and the endocrine pancreas |
Q38583953 | Dietary Fibre in Type II Diabetes |
Q51246154 | Different glucagon effects during DPP-4 inhibition versus SGLT-2 inhibition in metformin-treated type 2 diabetes patients. |
Q72223899 | Different mechanisms are involved in neuropeptide Y-induced pancreatic vasoconstriction and inhibition of insulin secretion |
Q54024294 | Differential changes in islet amyloid polypeptide (amylin) and insulin mRNA expression after high-fat diet-induced insulin resistance in C57BL/6J mice. |
Q36395742 | Differential development of glucose intolerance and pancreatic islet adaptation in multiple diet induced obesity models |
Q73158791 | Differential effect of insulin treatment on islet amyloid polypeptide (amylin) and insulin gene expression in streptozotocin-induced diabetes in rats |
Q43515497 | Differential effects of glucagon-like peptide-1 (7-36)amide versus cholecystokinin on arginine-induced islet hormone release in vivo and in vitro |
Q71172536 | Differential expression of islet amyloid polypeptide (amylin) and insulin in experimental diabetes in rodents |
Q43848935 | Differential impairment of glucagon responses to hypoglycemia, neuroglycopenia, arginine, and carbachol in alloxan-diabetic mice |
Q42164402 | Differential islet and incretin hormone responses in morning versus afternoon after standardized meal in healthy men. |
Q46878138 | Dipeptidyl peptidase 4 (DPP-4) is expressed in mouse and human islets and its activity is decreased in human islets from individuals with type 2 diabetes |
Q46832007 | Dipeptidyl peptidase-4 (DPP-4): Localization and activity in human and rodent islets |
Q44143356 | Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials |
Q31104386 | Dipeptidyl peptidase-4 inhibitors: clinical data and clinical implications |
Q31855529 | Direct cytoplasmic CA(2+) responses to gastrin-releasing peptide in single beta cells |
Q33968320 | Disassociated relation between plasma tumor necrosis factor-alpha, interleukin-6 and increased body weight in Amerindian women: A long-term prospective study of natural body weight variation and impaired glucose tolerance |
Q43163423 | Dissociated effects of glucose-dependent insulinotropic polypeptide vs glucagon-like peptide-1 on beta-cell secretion and insulin clearance in mice |
Q45926538 | Dissociated incretin response to oral glucose at 1 year after restrictive vs. malabsorptive bariatric surgery. |
Q73006830 | Dissociated insulinotropic sensitivity to glucose and carbachol in high-fat diet-induced insulin resistance in C57BL/6J mice |
Q36744260 | Disturbed alpha-cell function in mice with beta-cell specific overexpression of human islet amyloid polypeptide |
Q39054666 | Diurnal glucose exposure profiles of patients treated with lixisenatide before breakfast or the main meal of the day: An analysis using continuous glucose monitoring |
Q54113450 | Does galanin inhibit insulin secretion by opening of the ATP-regulated K+ channel in the beta-cell? |
Q44315351 | Dose-dependent inhibition by ghrelin of insulin secretion in the mouse |
Q54068522 | Dose-related effects of GLP-1 on insulin secretion, insulin sensitivity, and glucose effectiveness in mice. |
Q40303682 | Down-regulation of apolipoprotein M expression is mediated by phosphatidylinositol 3-kinase in HepG2 cells |
Q44414146 | Downregulation of islet hormone-sensitive lipase during long-term high-fat feeding |
Q45052330 | Dual action of adiponectin on insulin secretion in insulin-resistant mice |
Q68084167 | Dual effects of calcitonin gene-related peptide on insulin secretion in the perfused dog pancreas |
Q44576271 | Dual effects of pituitary adenylate cyclase-activating polypeptide and isoproterenol on lipid metabolism and signaling in primary rat adipocytes |
Q53331571 | Dual relation between leptin and cortisol in humans is disturbed in Alzheimer's disease. |
Q33317451 | Durable islet effects on insulin secretion and protein kinase A expression following exendin-4 treatment of high-fat diet-fed mice |
Q51497454 | Early and rapid development of insulin resistance, islet dysfunction and glucose intolerance after high-fat feeding in mice overexpressing phosphodiesterase 3B. |
Q69878472 | Effect and mechanism of vagal nerve stimulation on somatostatin secretion in dogs |
Q74582543 | Effect of 3-O-methylglucose on insulin secretion in the perfused dog and rat pancreas |
Q70216266 | Effect of Dietary Fibre on Blood Glucose, Plasma Immunoreactive Insulin, C-peptide and GIP Responses in non Insulin Dependent (Type 2) Diabetics and Controls |
Q90348841 | Effect of Liraglutide on Times in Glycaemic Ranges as Assessed by CGM for Type 2 Diabetes Patients Treated With Multiple Daily Insulin Injections |
Q46689843 | Effect of a conjugated linoleic acid and omega-3 fatty acid mixture on body composition and adiponectin |
Q72314127 | Effect of bile obstruction on liver regeneration following major hepatectomy: an experimental study in the rat |
Q72892797 | Effect of inhibition of protein synthesis on thyroid cyclic AMP accumulation in vitro |
Q64081823 | Effect of liraglutide on anthropometric measurements, sagittal abdominal diameter and adiponectin levels in people with type 2 diabetes treated with multiple daily insulin injections: evaluations from a randomized trial (MDI-liraglutide study 5) |
Q57222866 | Effect of phosphatidylcholine on postoperative adhesions after small bowel anastomosis in the rat |
Q48142030 | Effect of single-dose DPP-4 inhibitor sitagliptin on β-cell function and incretin hormone secretion after meal ingestion in healthy volunteers and drug-naïve, well-controlled type 2 diabetes subjects |
Q51294562 | Effect of the GLP-1 Receptor Agonist Lixisenatide on Counterregulatory Responses to Hypoglycemia in Subjects With Insulin-Treated Type 2 Diabetes. |
Q42467449 | Effects of 4-aminopyridine on insulin secretion and plasma glucose levels in intact and adrenalectomized-chemically sympathectomized mice |
Q68109833 | Effects of CCK-8 on the cytoplasmic free calcium concentration in isolated rat islet cells |
Q37696575 | Effects of DPP-4 inhibitor linagliptin and GLP-1 receptor agonist liraglutide on physiological response to hypoglycaemia in Japanese subjects with type 2 diabetes: A randomized, open-label, 2-arm parallel comparative, exploratory trial |
Q40095941 | Effects of Dexamethasone, Desoxycorticosterone, and ACTH on Serum Concentrations of Thyroxine, 3, 5, 3′-Triiodothyronine and 3, 3‘, 5’-Triiodothyronine |
Q71813539 | Effects of GLP-1 and 2,5-anhydro-D-mannitol on insulin secretion and plasma glucose in mice |
Q67464635 | Effects of Galanin and Norepinephrine on Insulin Secretion in the Mouse |
Q69897096 | Effects of alpha 1- and alpha 2-adrenoceptor stimulation and blockade on plasma insulin levels in the mouse |
Q72572298 | Effects of alpha 1-, alpha 2- and beta-adrenoceptor blockers on insulin secretion in the rat |
Q69870874 | Effects of alpha- and beta-adrenoceptor stimulation on 45Ca2+ efflux and insulin secretion from perfused rat islets |
Q69873953 | Effects of alpha-adrenoceptor blockade by phentolamine on basal and stimulated insulin secretion in the mouse |
Q51587077 | Effects of arginine on the secretion of insulin and islet amyloid polypeptide in humans. |
Q51867889 | Effects of autonomic blockade by methylatropine and optical isomers and propranolol on plasma insulin levels in the basal state and after stimulation. |
Q43521338 | Effects of calcitonin gene-related peptide (CGRP) on islet hormone secretion in the pig. |
Q32062812 | Effects of chemical sympathectomy by means of 6-hydroxydopamine on insulin secretion and islet morphology in alloxan-diabetic mice |
Q43947295 | Effects of cholecystokinin (CCK)-8, CCK-33, and gastric inhibitory polypeptide (GIP) on basal and meal-stimulated pancreatic hormone secretion in man |
Q70942088 | Effects of cholecystokinin and glucagon-like peptide 1 on the secretion of pancreatic polypeptide in mice |
Q44985760 | Effects of conjugated linoleic acid plus n-3 polyunsaturated fatty acids on insulin secretion and estimated insulin sensitivity in men. |
Q48136280 | Effects of corticotropin-releasing hormone on insulin and glucagon secretion in mice. |
Q69090891 | Effects of galanin on insulin and glucagon secretion in the rat |
Q70942060 | Effects of galanin on proinsulin mRNA and insulin biosynthesis in normal islets |
Q42467000 | Effects of glicentine on insulin secretion |
Q68900574 | Effects of glipizide on various consecutive insulin secretory stimulations in patients with type 2 diabetes |
Q71526624 | Effects of glucagon and pentagastrin on glibenclamide-induced insulin release |
Q72693519 | Effects of glucagon like peptide-1(7-36) amide on the cytoplasmic Ca(2+)-concentration in rat islet cells |
Q53886146 | Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. |
Q51577056 | Effects of glucagon-like peptide-1 on islet function and insulin sensitivity in noninsulin-dependent diabetes mellitus. |
Q51581175 | Effects of glucagon-like peptide-I on glucose turnover in rats. |
Q44921536 | Effects of high-fat feeding and fasting on ghrelin expression in the mouse stomach |
Q35801801 | Effects of increasing doses of glucagon-like peptide-1 on insulin-releasing phases during intravenous glucose administration in mice |
Q72393119 | Effects of naloxone on basal and stimulated insulin secretion in the mouse |
Q70143998 | Effects of norepinephrine on basal and thyrotropin-stimulated thyroid hormone secretion in the mouse |
Q69930371 | Effects of pancreatic noradrenaline infusion on basal and stimulated islet hormone secretion in the dog |
Q72707636 | Effects of pectin on glycaemia and insulinaemia after starch loading in normal, alloxan diabetic, and pancreatic duct-occluded rats |
Q42465957 | Effects of porcine diazepam-binding inhibitor on insulin and glucagon secretion in vitro from the rat endocrine pancreas |
Q72475533 | Effects of selective and non-selective β-adrenergic agents on insulin secretion in vivo |
Q44212936 | Effects of six cholecystokinin (CCK) fragments on insulin secretion in the mouse. |
Q42488166 | Effects of the three neuropeptides, vasoactive intestinal peptide, substance P, and calcitonin gene related peptide on basal and stimulated calcitonin release in the rat. |
Q69491589 | Effects of three different cholecystokinin receptor antagonists on basal and stimulated insulin and glucagon secretion in mice |
Q67259585 | Effects of thyrotrophin stimulation for two hours on mouse thyroid cyclic AMP levels in vivo and in vitro |
Q67276620 | Effects of vasoactive intestinal polypeptide (VIP), secretin and gastrin on insulin secretion in the mouse |
Q72555240 | Effects of β-adrenoceptor agonists and antagonists on thyroid hormone secretion |
Q88338508 | Effects on the glucagon response to hypoglycaemia during DPP-4 inhibition in elderly subjects with type 2 diabetes: A randomized, placebo-controlled study |
Q40422929 | Efficacy and Cardiovascular Safety of Linagliptin as an Add-On to Insulin in Type 2 Diabetes: A Pooled Comprehensive Post Hoc Analysis |
Q51593492 | Efficacy and Safety of Liraglutide Added to Capped Insulin Treatment in Subjects With Type 1 Diabetes: The ADJUNCT TWO Randomized Trial. |
Q37106572 | Efficacy and safety of lixisenatide once-daily morning or evening injections in type 2 diabetes inadequately controlled on metformin (GetGoal-M). |
Q53372791 | Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial. |
Q87595911 | Efficacy of lixisenatide in patients with type 2 diabetes: A post hoc analysis of patients with diverse β-cell function in the GetGoal-M and GetGoal-S trials |
Q87558803 | Efficacy of vildagliptin versus sulfonylureas as add-on therapy to metformin: comparison of results from randomised controlled and observational studies |
Q82787527 | Emerging dipeptidyl peptidase-4 inhibitors for the treatment of diabetes |
Q40360642 | Enhanced insulin sensitivity mediated by adipose tissue browning perturbs islet morphology and hormone secretion in response to autonomic nervous activation in female mice |
Q72538452 | Enhancement of insulin secretion during selective blockade of alpha 1- and alpha 2-adrenoceptors in the rat: effects of somatostatin |
Q51319202 | Equal improvement in glycaemia with lixisenatide given before breakfast or the main meal of the day. |
Q44808610 | Estimated intake of milk fat is negatively associated with cardiovascular risk factors and does not increase the risk of a first acute myocardial infarction. A prospective case-control study |
Q37222837 | Estimation of the Relative Contribution of Postprandial Glucose Exposure to Average Total Glucose Exposure in Subjects with Type 2 Diabetes. |
Q72789853 | Evidence for an influence of the peri-arterial hepatic nerves on basal insulin-secretion in the rat |
Q40992469 | Evidence for contribution by increased cytoplasmic Na+ to the insulinotropic action of PACAP38 in HIT-T15 cells |
Q51566222 | Evidence for leptin regulation of food intake in humans. |
Q87502480 | Evidence for neural contribution to islet effects of DPP-4 inhibition in mice |
Q54641355 | Evidence for the presence of glucose cycling in pancreatic islets of the ob/ob mouse. |
Q87094005 | Evidence for time dependent variation of glucagon secretion in mice |
Q46931625 | Evidence that oestrogen receptor-alpha plays an important role in the regulation of glucose homeostasis in mice: insulin sensitivity in the liver |
Q38325069 | Extensive islet amyloid formation is induced by development of Type II diabetes mellitus and contributes to its progression: pathogenesis of diabetes in a mouse model |
Q68251444 | Extraction of epinephrine and norepinephrine by the dog pancreas in vivo |
Q72928143 | Factors influencing the release of cyclic AMP from mouse thyroid tissue stimulated by TSH in vitro |
Q68504056 | Failure of islet amyloid polypeptide to inhibit basal and glucose-stimulated insulin secretion in model experiments in mice and rats |
Q44303373 | Failure of somatostatin to eliminate the glucagon release induced by baroreceptor unloading in the cat |
Q51579831 | Failure to adequately adapt reduced insulin sensitivity with increased insulin secretion in women with impaired glucose tolerance. |
Q51587936 | Fasting blood glucose in determining the prevalence of diabetes in a large, homogeneous population of Caucasian middle-aged women. |
Q35721830 | Fasting until noon triggers increased postprandial hyperglycemia and impaired insulin response after lunch and dinner in individuals with type 2 diabetes: a randomized clinical trial |
Q44449211 | Fat feeding impairs glycogen synthase activity in mice without effects on its gene expression |
Q86026330 | Fibroblast growth factor 21 (FGF21) and glucagon-like peptide 1 contribute to diabetes resistance in glucagon receptor-deficient mice |
Q51300354 | Fibroblast growth factor 21 prevents glycemic deterioration in insulin deficient mouse models of diabetes. |
Q46173840 | Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy |
Q35846876 | Four-Point Preprandial Self-Monitoring of Blood Glucose for the Assessment of Glycemic Control and Variability in Patients with Type 2 Diabetes Treated with Insulin and Vildagliptin |
Q35661969 | Four-Year Durability of Initial Combination Therapy with Sitagliptin and Metformin in Patients with Type 2 Diabetes in Clinical Practice; COSMIC Study |
Q36892888 | Function of reduced-size liver transplant in the rat. |
Q27865197 | G-protein-coupled receptors and islet function-implications for treatment of type 2 diabetes. |
Q42472192 | GLP-1 and GLP-1(7-36) amide: influences on basal and stimulated insulin and glucagon secretion in the mouse |
Q33794098 | GLP-1 for type 2 diabetes |
Q36012529 | GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes |
Q33745485 | GLP-1 released to the mesenteric lymph duct in mice: effects of glucose and fat. |
Q38554472 | GLP-1 tablet in type 2 diabetes in fasting and postprandial conditions |
Q67961395 | GLP-1(7-36)amide-stimulated insulin secretion in rat islets is sodium-dependent |
Q37049674 | GLP-1-based therapy of type 2 diabetes: GLP-1 mimetics and DPP-IV inhibitors |
Q51800702 | GPR40 is expressed in glucagon producing cells and affects glucagon secretion. |
Q38185571 | Galanin and the endocrine pancreas |
Q35335134 | Galanin and the regulation of islet hormone secretion. |
Q73521763 | Galanin exerts dual action on inositol-specific phospholipase C activity in isolated pancreatic islets |
Q67699395 | Galanin fragments and analogues: effects on glucose-stimulated insulin secretion from isolated rat islets |
Q69045811 | Galanin inhibits amylase secretion from isolated rat pancreatic acini |
Q68977942 | Galanin inhibits glucose-stimulated insulin release by a mechanism involving hyperpolarization and lowering of cytoplasmic free Ca2+ concentration |
Q67666998 | Galanin is co-localized with noradrenaline and neuropeptide Y in dog pancreas and celiac ganglion |
Q71655908 | Galanin message-associated polypeptide (GMAP) does not affect insulin secretion from isolated islets |
Q67676195 | Galanin of the homologous species inhibits insulin secretion in the rat and in the pig |
Q28324014 | Galanin-immunoreactive nerves in the mouse and rat pancreas |
Q67711020 | Galanin-induced inhibition of insulin secretion from rat islets: effects of rat and pig galanin and galanin fragments and analogues |
Q36699745 | Galanin-receptor ligand M40 peptide distinguishes between putative galanin-receptor subtypes |
Q68967530 | Galanin: a novel pancreatic neuropeptide |
Q68993054 | Galanin: effects on basal and stimulated insulin and glucagon secretion in the mouse |
Q81880884 | Gastric carcinoids: biologic behavior and prognosis after differentiated treatment in relation to type |
Q68084952 | Gastrin releasing peptide stimulates the secretion of insulin, but not that of glucagon or somatostatin, from the isolated perfused dog pancreas |
Q41245760 | Gastrin-releasing peptide mobilizes calcium from intracellular stores in HIT-T15 cells |
Q43822360 | Gender difference in the glucagon response to glucopenic stress in mice |
Q51473372 | Gender-specific links between hepatic 11beta reduction of cortisone and adipokines. |
Q50891529 | Glucagon and GLP-1 exhibit no synergistic enhancement of glucose-stimulated insulin secretion in mice |
Q93271430 | Glucagon and insulin secretion, insulin clearance, and fasting glucose in GIP receptor and GLP-1 receptor knockout mice |
Q37626422 | Glucagon clearance is regulated by nutritional state: evidence from experimental studies in mice |
Q57563922 | Glucagon dynamics during hypoglycaemia and food-re-challenge following treatment with vildagliptin in insulin-treated patients with type 2 diabetes |
Q72670214 | Glucagon immunoreactivity in plasma from normal and dystrophic mice |
Q46212121 | Glucagon increases insulin levels by stimulating insulin secretion without effect on insulin clearance in mice |
Q33283676 | Glucagon receptor antagonism improves islet function in mice with insulin resistance induced by a high-fat diet |
Q79386784 | Glucagon receptor knockout mice display increased insulin sensitivity and impaired beta-cell function |
Q38392884 | Glucagon--Early breakthroughs and recent discoveries |
Q51063362 | Glucagon-like peptide-1 accelerates the onset of insulin action on glucose disappearance in mice |
Q33800196 | Glucagon-like peptide-1 and glucose-dependent insulinotropic peptide: effects alone and in combination on insulin secretion and glucose disappearance in mice |
Q90901449 | Glucagon-like peptide-1 receptor agonists for type 2 diabetes: A rational drug development |
Q58449011 | Glucagon-like peptide-1 reduces hepatic glucose production indirectly through insulin and glucagon in humans |
Q71589117 | Glucagon-like peptide-1(7-36)amide and cytoplasmic calcium in insulin producing cells |
Q100959656 | Glucose Effectiveness Lessons from Studies on Insulin-Independent Glucose Clearance in Mice |
Q72278232 | Glucose homeostasis after peri-arterial hepatic denervation in partially hepatectomized rats |
Q44717417 | Glucose intolerance is predicted by low insulin secretion and high glucagon secretion: outcome of a prospective study in postmenopausal Caucasian women |
Q51587985 | Glucose modulation of insulin and glucagon secretion is altered in impaired glucose tolerance. |
Q68942609 | Glucose tolerance and insulin and C-peptide responses after various insulin secretory stimuli in hyper- and hypothyroid subjects before and after treatment |
Q70593888 | Glucose tolerance and insulin secretion in experimental pancreatic cancer in the Syrian hamster |
Q68533404 | Glucose tolerance and insulin secretion in experimental peritonitis in the rat |
Q51618486 | Glucose turnover in rats undergoing transient dearterialization for liver malignancy. |
Q47755819 | Glucose-dependent arginine stimulation test for characterization of islet function: studies on reproducibility and priming effect of arginine |
Q83181276 | Glucose-induced incretin hormone release and inactivation are differently modulated by oral fat and protein in mice |
Q46985413 | Glucose-stimulated insulin secretion correlates with beta-cell lipolysis |
Q34265490 | Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis |
Q46808831 | Glycogen and glycogen-hydrolysing lysosomal enzyme activity in mouse liver: effects of fasting, adrenoceptor antagonism and insulin-induced hypoglycaemia |
Q45096607 | Growth hormone deficiency predicts cardiovascular risk in young adults treated for acute lymphoblastic leukemia in childhood |
Q45199123 | Growth hormone overexpression in the central nervous system results in hyperphagia-induced obesity associated with insulin resistance and dyslipidemia |
Q31157033 | Gut peptides and type 2 diabetes mellitus treatment |
Q51321425 | HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin. |
Q51562487 | Habitual dietary intake versus glucose tolerance, insulin sensitivity and insulin secretion in postmenopausal women. |
Q68182434 | Hepatic sympathetic denervation potentiates glucagon-stimulated glycogenolysis and hyperinsulinaemia in the rat |
Q86826081 | Hepato-incretin function of GLP-1: novel concept and target in type 1 diabetes |
Q60639601 | High CSF-insulin in violent suicide attempters |
Q48420056 | High leptin levels are associated with stroke |
Q47190755 | High-energy breakfast based on whey protein reduces body weight, postprandial glycemia and HbA1C in Type 2 diabetes |
Q86842730 | High-energy breakfast with low-energy dinner decreases overall daily hyperglycaemia in type 2 diabetic patients: a randomised clinical trial |
Q34726350 | Higher Risk of Hypoglycemia with Glimepiride Versus Vildagliptin in Patients with Type 2 Diabetes is not Driven by High Doses of Glimepiride: Divergent Patient Susceptibilities? |
Q44497632 | Hormone-sensitive lipase null mice exhibit signs of impaired insulin sensitivity whereas insulin secretion is intact |
Q36662603 | Human islet amyloid polypeptide transgenic mice: in vivo and ex vivo models for the role of hIAPP in type 2 diabetes mellitus |
Q24625957 | Identification, isolation, and characterization of daintain (allograft inflammatory factor 1), a macrophage polypeptide with effects on insulin secretion and abundantly present in the pancreas of prediabetic BB rats |
Q70223138 | Immunoreactive insulin and C-peptide responses to various insulin secretory stimuli in subjects with type 2 diabetes and in control subjects during continuous glucose monitoring |
Q33902884 | Impact of glucose dosing regimens on modeling of glucose tolerance and β-cell function by intravenous glucose tolerance test in diet-induced obese mice |
Q51573060 | Impaired adaptation of first-phase insulin secretion in postmenopausal women with glucose intolerance. |
Q44564070 | Impaired cathepsin L gene expression in skeletal muscle is associated with type 2 diabetes |
Q43806842 | Impaired glucose tolerance (IGT) is associated with reduced insulin-induced suppression of glucagon concentrations |
Q43720039 | Impaired incretin response after a mixed meal is associated with insulin resistance in nondiabetic men. |
Q35649213 | Importance of quantifying insulin secretion in relation to insulin sensitivity to accurately assess beta cell function in clinical studies |
Q28565526 | Important role of phosphodiesterase 3B for the stimulatory action of cAMP on pancreatic beta-cell exocytosis and release of insulin |
Q44295533 | Improved beta-cell function after standardized weight reduction in severely obese subjects |
Q35928257 | Improved glucose regulation in type 2 diabetic patients with DPP-4 inhibitors: focus on alpha and beta cell function and lipid metabolism |
Q54153850 | Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice. |
Q70287284 | Improved insulin release to carbachol after vagotomy in rats-an effect due to cholinergic supersensitivity of the β-cells? |
Q33509686 | Improved insulin sensitivity and islet function after PPARdelta activation in diabetic db/db mice |
Q33220335 | Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year |
Q46907739 | Improved meal-related insulin processing contributes to the enhancement of B-cell function by the DPP-4 inhibitor vildagliptin in patients with type 2 diabetes |
Q39799361 | Improved metabolic risk markers following two 6-month physical activity programs among socioeconomic marginalized women of Native American ancestry in Lima, Peru |
Q46979672 | Improvement in cardiac systolic function and reduced prevalence of metabolic syndrome after two years of growth hormone (GH) treatment in GH-deficient adult survivors of childhood-onset acute lymphoblastic leukemia. |
Q69798468 | Improvement of liver preservation quality with UW solution by chlorpromazine pretreatment of the donor in an experimental model |
Q67980093 | Improvement of the effects of intrasplenic transplantation of hepatocytes after 90% hepatectomy in the rat by cotransplantation with pancreatic islets |
Q46917075 | In vivo and in vitro glucose-induced biphasic insulin secretion in the mouse: pattern and role of cytoplasmic Ca2+ and amplification signals in beta-cells |
Q47558789 | Increased insulin clearance in mice with double deletion of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors |
Q50864761 | Increased insulin secretion and glucose tolerance in mice lacking islet amyloid polypeptide (amylin). |
Q43852281 | Increased insulin secretion in response to glucose in isolated islets of Langerhans from bile duct-occluded rats |
Q44357255 | Increased insulin sensitivity is associated with reduced insulin and glucagon secretion and increased insulin clearance in man. |
Q54685218 | Increased passage of bovine serum albumin over the respiratory tract after intratracheal instillation during septic shock in rats. |
Q51531645 | Increased β-cell volume in mice fed a high-fat diet: a dynamic study over 12 months |
Q46494673 | Incretin and islet hormonal responses to fat and protein ingestion in healthy men. |
Q47426813 | Incretin and islet hormone responses to meals of increasing size in healthy subjects |
Q53365314 | Incretin effect after oral amino acid ingestion in humans. |
Q51032753 | Incretin hormone and insulin responses to oral versus intravenous lipid administration in humans |
Q50915104 | Incretin hormone receptors are required for normal beta cell development and function in female mice |
Q37811413 | Incretin hormone secretion over the day. |
Q83858750 | Incretin hormones and the up-regulation of insulin secretion in insulin resistance |
Q87368933 | Incretin, insulinotropic and glucose-lowering effects of whey protein pre-load in type 2 diabetes: a randomised clinical trial |
Q91676517 | Incretin-based medications (GLP-1 receptor agonists, DPP-4 inhibitors) as a means to avoid hypoglycaemic episodes |
Q68862818 | Influence of bile duct occlusion on plasma insulin responses to glucose in rats |
Q70503575 | Influence of peri-arterial hepatic denervation on the glycemic response to exercise in rats |
Q68452003 | Influence of phosphatidylcholine on intra-abdominal adhesion formation and peritoneal macrophages |
Q42446149 | Influence of the sympatho-adrenal system and somatostatin on the secretion of insulin in the rat |
Q48200185 | Influences of Breakfast on Clock Gene Expression and Postprandial Glycemia in Healthy Individuals and Individuals With Diabetes: A Randomized Clinical Trial. |
Q72684099 | Influences of Gastro-Intestinal Polypeptides and Glucose on Glucagon Secretion Induced by Cholinergic Stimulation |
Q72161963 | Inhibition by rat diazepam-binding inhibitor/acyl-CoA-binding protein of glucose-induced insulin secretion in the rat |
Q40103150 | Inhibition by somatostatin of mouse thyroid activity following stimulation by thyrotrophin, isoprenaline and dibutyryl cyclic-AMP |
Q69904267 | Inhibition of 2-deoxy-glucose-induced glucagon secretion by muscarinic and alpha-adrenoceptor blockade in the mouse |
Q43972608 | Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes |
Q81157658 | Inhibition of dipeptidyl peptidase-4 augments insulin secretion in response to exogenously administered glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, pituitary adenylate cyclase-activating polypeptide, and gastrin-releasing |
Q28260260 | Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes |
Q44704981 | Inhibition of lipase activity and lipolysis in rat islets reduces insulin secretion |
Q35871904 | Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of Type 2 diabetes? |
Q37611960 | Inhibitory effect of kisspeptins on insulin secretion from isolated mouse islets |
Q41114034 | Inhibitory effect of somatostatin on insulin secretion during alpha-adrenergic blockade in three different species |
Q44129319 | Insufficient islet compensation to insulin resistance vs. reduced glucose effectiveness in glucose-intolerant mice |
Q51280702 | Insulin Resistance Is Accompanied by Increased Fasting Glucagon and Delayed Glucagon Suppression in Individuals With Normal and Impaired Glucose Regulation. |
Q68159132 | Insulin and C-peptide secretory responses to glucagon in man: studies on the dose-response relationships |
Q74456442 | Insulin and glucagon secretion by ganglionic nicotinic activation in adrenalectomized mice |
Q42504927 | Insulin and glucagon secretion in rats: effects of calcitonin gene-related peptide |
Q69275582 | Insulin and glucagon secretion in streptozotocin-diabetic rats: influences of islets transplanted to the renal subcapsular space |
Q70164174 | Insulin and glucagon secretion in swimming mice: effects of adrenalectomy and chemical sympathectomy |
Q44745649 | Insulin and glucagon secretion in swimming mice: effects of autonomic receptor antagonism |
Q64228179 | Insulin and incretin hormone responses to rapid versus slow ingestion of a standardized solid breakfast in healthy subjects |
Q37598881 | Insulin plus incretin: A glucose-lowering strategy for type 2-diabetes |
Q51560877 | Insulin resistant subjects lack islet adaptation to short-term dexamethasone-induced reduction in insulin sensitivity. |
Q33224079 | Insulin secretion after dietary supplementation with conjugated linoleic acids and n-3 polyunsaturated fatty acids in normal and insulin-resistant mice |
Q44887107 | Insulin secretion and incretin hormones after oral glucose in non-obese subjects with impaired glucose tolerance |
Q33275901 | Insulin secretion and insulin sensitivity in relation to fasting glucose in healthy subjects |
Q42491276 | Insulin secretion and islet lysosomal enzyme activities in the mouse. Effects of suramin. |
Q42045839 | Insulin secretion and lysosomal enzyme activities in isolated mouse islets. Effects of glucose, diazoxide and isobutylmethylxanthine. |
Q74153623 | Insulin secretion by gastrin-releasing peptide in mice: ganglionic versus direct islet effect |
Q69315563 | Insulin secretion in neonatally streptozotocin-injected mice |
Q43564357 | Insulin secretion in rats: effects of neuropeptide Y and noradrenaline |
Q70122003 | Insulin secretion in streptozotocin-diabetic rats transplanted with immunoisolated islets |
Q72513743 | Insulin secretion induced by glucose and by stimulation of beta 2 -adrenoceptors in the rat. Different sensitivity to somatostatin |
Q72491194 | Insulin secretory response to different secretagogues in hyper- and hypothyroid mice |
Q44616504 | Insulin sensitivity, insulin secretion, and glucose tolerance versus intima-media thickness in nondiabetic postmenopausal women |
Q52544667 | Insulin-like growth factor II plays a central role in atherosclerosis in a mouse model. |
Q72545349 | Interaction of gastric inhibitory polypeptide (GIP) and cholecystokinin (CCK-8) with basal and stimulated insulin secretion in mice |
Q44913553 | Interactions between fibrinolysis, lipoproteins and leptin related to a first myocardial infarction |
Q43851625 | Interleukin-6-deficient mice develop mature-onset obesity |
Q43591084 | Intermittent hepatic arterial or portal occlusion reduces liver tumor growth |
Q42481230 | Intermittent hepatic dearterialization induces glucose intolerance: an experimental study in the rat. |
Q73476404 | Intraperitoneal PACAP administration decreases blood glucose in GK rats, and in normal and high fat diet mice |
Q72762392 | Involvement of capsaicin-sensitive nerves in regulation of insulin secretion and glucose tolerance in conscious mice |
Q71583350 | Involvement of nitric oxide in neuroglycopenia-induced insulin and glucagon secretion in the mouse |
Q71712887 | Involvement of phospholipase A2 and arachidonic acid in cholecystokinin-8-induced insulin secretion in rat islets |
Q39030736 | Ischaemic and metabolic treatment of hepatic tumours |
Q37443837 | Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes |
Q90113735 | Islet adaptation in GIP receptor knockout mice |
Q36005145 | Islet adaptation to insulin resistance: mechanisms and implications for intervention |
Q67875638 | Islet allotransplantation to streptozotocin-diabetic rats. Effects of multistrain donation and ultraviolet light irradiation |
Q33912902 | Islet amyloid and type 2 diabetes mellitus |
Q71469934 | Islet amyloid polypeptide (amylin) and insulin are differentially expressed in chronic diabetes induced by streptozotocin in rats |
Q73634180 | Islet amyloid polypeptide (amylin)-deficient mice develop a more severe form of alloxan-induced diabetes |
Q51578239 | Islet amyloid polypeptide and insulin gene expression are regulated in parallel by glucose in vivo in rats. |
Q51556021 | Islet dysfunction in insulin resistance involves impaired insulin secretion and increased glucagon secretion in postmenopausal women with impaired glucose tolerance. |
Q51582214 | Islet dysfunction in obese women with impaired glucose tolerance. |
Q44142711 | Islet function phenotype in gastrin-releasing peptide receptor gene-deficient mice |
Q41946992 | Islet hormone secretion and islet lysosomal enzyme activities in the mouse: effects of chloroquine. |
Q73838344 | Islet phospholipase A(2) activation is potentiated in insulin resistant mice |
Q69261583 | Islet transplantation to the renal subcapsular space in streptozotocin-diabetic rats. Long-term effects on insulin and glucagon secretion |
Q69243778 | Kinetics of radioiodine released from prelabelled thyroid gland in vivo: influence of propylthiouracil |
Q39181694 | Large differences in serum leptin levels between nonwesternized and westernized populations: the Kitava study |
Q43844459 | Leptin concentrations are increased in subjects treated with clozapine or conventional antipsychotics |
Q48290307 | Leptin is a risk marker for first-ever hemorrhagic stroke in a population-based cohort |
Q54070456 | Leptin is associated with increased risk of myocardial infarction. |
Q80043586 | Leptin is closely related to body fat in prepubertal children aged 8-11 years |
Q57938596 | Leptin is reduced in lean subjects with type 2 diabetes in bangladesh |
Q50912358 | Leptin--a regulator of islet function?: its plasma levels correlate with glucagon and insulin secretion in healthy women |
Q36220895 | Liraglutide in people treated for type 2 diabetes with multiple daily insulin injections: randomised clinical trial (MDI Liraglutide trial) |
Q68015734 | Liver cirrhosis in rats: regeneration and assessment of the role of phenobarbital |
Q70733685 | Liver regeneration following 68% partial orthotopic liver transplantation in the rat |
Q43651804 | Liver-derived IGF-I is of importance for normal carbohydrate and lipid metabolism. |
Q44419324 | Local Growth Factors Are Beneficial for the Autonomic Reinnervation of Transplanted Islets in Rats |
Q44971975 | Localization of calcitonin gene-related peptide and islet amyloid polypeptide in the rat and mouse pancreas |
Q70528849 | Long-term diabetogenic effect of streptozotocin in rats |
Q71923179 | Long-term effects of alloxan in mice |
Q43973972 | Long-term inhibition of dipeptidyl peptidase IV improves glucose tolerance and preserves islet function in mice |
Q74141538 | Long-term leptin treatment of ob/ob mice improves glucose-induced insulin secretion |
Q44814498 | Loss-of-function mutation of the galanin gene is associated with perturbed islet function in mice |
Q47380156 | Low CSF leptin in female suicide attempters with major depression |
Q42476819 | Low adipocyte IRS-1 protein expression is associated with an increased arterial stiffness in non-diabetic males |
Q39181702 | Low serum insulin in traditional Pacific Islanders--the Kitava Study |
Q54116263 | Marked hyperleptinemia after high-fat diet associated with severe glucose intolerance in mice. |
Q61480334 | Mature-Onset Obesity in Interleukin-1 Receptor I Knockout Mice |
Q37867193 | Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans |
Q72371088 | Mechanisms underlying the insulinostatic effect of peptide YY in mouse pancreatic islets |
Q41564006 | Methods and models for metabolic assessment in mice |
Q45056312 | Milrinone efficiently potentiates insulin secretion induced by orally but not intravenously administered glucose in C57BL6J mice |
Q68270083 | Mitomycin C and lipiodol do not improve the effect of intermittent hepatic artery occlusion on liver tumour growth. An experimental study in the rat |
Q40557047 | Mixed meal ingestion diminishes glucose excursion in comparison with glucose ingestion via several adaptive mechanisms in people with and without type 2 diabetes |
Q70233490 | Modulation of basal insulin secretion in the obese, hyperglycemic mouse |
Q74631706 | Modulatory role of adrenergic nerves on dexamethasone-induced islet cell NPY expression in the rat: evidence from chemical sympathectomy |
Q69552062 | Monoamines in pancreatic islets of guinea pig, hamster, rat, and mouse determined by high performance liquid chromatography |
Q71664555 | N-terminally elongated fragments of galanin(1-16) inhibit insulin secretion from isolated mouse islets |
Q28316273 | Neonatal capsaicin-treatment in mice: effects on pancreatic peptidergic nerves and 2-deoxy-D-glucose-induced insulin and glucagon secretion |
Q42212928 | Neuropeptide Y and calcitonin gene-related peptide: effects on glucagon and insulin secretion in the mouse |
Q48068593 | Neuropeptide Y is expressed in subpopulations of insulin- and non-insulin-producing islet cells in the rat after dexamethasone treatment: a combined immunocytochemical and in situ hybridisation study |
Q42522242 | Neuropeptide Y: intrapancreatic neuronal localization and effects on insulin secretion in the mouse |
Q39462385 | Neuropeptidergic versus cholinergic and adrenergic regulation of islet hormone secretion |
Q72701024 | Neuropeptides in the Thyroid Gland: Distribution of Substance P and Gastrin/Cholecystokinin and Their Effects on the Secretion of Iodothyronine and Calcitonin* |
Q36525819 | Neuropeptides in the regulation of islet hormone secretion--localization, effects and mode of action |
Q46400145 | New strategy in type 2 diabetes tested in clinical trials. Glucagon-like peptide 1 (GLP-1) affects basic caused of the disease |
Q51572132 | No correlation between insulin and islet amyloid polypeptide after stimulation with glucagon-like peptide-1 in type 2 diabetes. |
Q72348992 | Non-parallelism of islet amyloid polypeptide (amylin) and insulin gene expression in rats islets following dexamethasone treatment |
Q69928277 | Nonadrenergic sympathetic neural influences on basal pancreatic hormone secretion |
Q36812821 | Novel combination treatment of type 2 diabetes DPP-4 inhibition + metformin |
Q69106993 | On the nature of the galanin action on the endocrine pancreas: studies with six galanin fragments in the perfused dog pancreas |
Q53737560 | Once weekly glucagon-like peptide-1 receptor agonist albiglutide vs. prandial insulin added to basal insulin in patients with type 2 diabetes mellitus: Results over 52 weeks. |
Q42831349 | Overexpression of Foxf2 in adipose tissue is associated with lower levels of IRS1 and decreased glucose uptake in vivo |
Q32076408 | Overweight is associated with lower serum leptin in Peruvian Indian than in Caucasian women: A dissociation contributing to low blood pressure? |
Q58448777 | PACAP contributes to insulin secretion after gastric glucose gavage in mice |
Q74612429 | PACAP is an islet neuropeptide which contributes to glucose-stimulated insulin secretion |
Q44397753 | PACAP is expressed in secretory granules of insulin and glucagon cells in human and rodent pancreas. Evidence for generation of cAMP compartments uncoupled from hormone release in diabetic islets |
Q48014626 | PACAP stimulates insulin secretion but inhibits insulin sensitivity in mice |
Q40825758 | PACAP27 sensitizes glucose induced insulin secretion in INS-1 cells |
Q44618182 | Pancreastatin inhibits insulin secretion and exocrine pancreatic secretion in the pig. |
Q68139524 | Pancreastatin inhibits insulin secretion and stimulates glucagon secretion in mice |
Q43466841 | Pancreastatin inhibits insulin secretion from isolated rat islets: studies on its mechanism of action |
Q71697302 | Pancreastatin modulates glucose-stimulated insulin secretion from the perfused rat pancreas |
Q43579253 | Pancreatic Release of Pancreastatin in the Pig |
Q44527061 | Pancreatic beta-cell lipotoxicity induced by overexpression of hormone-sensitive lipase |
Q54566890 | Pancreatic exocrine secretion during the first days after weaning in pigs. |
Q42465732 | Pancreatic function in the essential fatty acid deficient rat |
Q69104272 | Pancreatic nerve stimulation releases neuropeptide Y- but not galanin- or calcitonin gene-related peptide-like immunoreactivity from the pig pancreas |
Q72746749 | Pancreatic peptide YY in alloxan diabetic mice |
Q44255639 | Pancreatic procolipase activation peptide-enterostatin-inhibits pancreatic enzyme secretion in the pig. |
Q67522369 | Pancreatic tumors in multiple endocrine neoplasia type 1: clinical presentation and surgical treatment |
Q42516766 | Peptide YY does not inhibit glucose-stimulated insulin secretion in humans |
Q42496974 | Peptide YY: intrapancreatic localization and effects on insulin and glucagon secretion in the mouse. |
Q68078458 | Peptide receptor antagonists in the study of insulin and glucagon secretion in mice |
Q91596747 | Persistent whole day meal effects of three dipeptidyl peptidase-4 inhibitors on glycaemia and hormonal responses in metformin-treated type 2 diabetes |
Q68207435 | Phosphatidylcholine prevents postoperative peritoneal adhesions: an experimental study in the rat |
Q33918661 | Phospholipase A2 and its potential regulation of islet function |
Q54250223 | Phospholipase-resistant phosphatidylcholine reduces intra-abdominal adhesions induced by bacterial peritonitis. |
Q35760279 | Physiology of incretins in health and disease |
Q41144147 | Pituitary adenylate cyclase-activating polypeptide (PACAP) and insulin secretion: effects and mechanisms |
Q42456246 | Pituitary adenylate cyclase-activating polypeptide (PACAP): occurrence in rodent pancreas and effects on insulin and glucagon secretion in the mouse |
Q73668365 | Pituitary adenylate cyclase-activating polypeptide stimulates insulin and glucagon secretion in humans |
Q46831311 | Plasma calcitonin gene-related peptide is increased prior to obesity, and sensory nerve desensitization by capsaicin improves oral glucose tolerance in obese Zucker rats |
Q54092903 | Plasma leptin levels are associated with abnormal fibrinolysis in men and postmenopausal women. |
Q51578920 | Plasma leptin levels correlate to islet function independently of body fat in postmenopausal women. |
Q51386462 | Plasma lipid fatty acid composition, desaturase activities and insulin sensitivity in Amerindian women |
Q67535249 | Plasma neuropeptide Y (NPY) and galanin before and during exercise in type 1 diabetic patients with autonomic dysfunction |
Q51320196 | Pleiotropic mechanisms for the glucose-lowering action of DPP-4 inhibitors. |
Q43708974 | Positive correlation between tumor necrosis factor (TNF)-α and cardiorespiratory fitness after six-months of regular aerobic exercise in Peruvian Amerindian women |
Q44397771 | Postnatally disturbed pancreatic islet cell distribution in human islet amyloid polypeptide transgenic mice |
Q37239290 | Postprandial Glucagon Reductions Correlate to Reductions in Postprandial Glucose and Glycated Hemoglobin with Lixisenatide Treatment in Type 2 Diabetes Mellitus: A Post Hoc Analysis |
Q40931940 | Potential therapeutic levels of glucagon-like peptide I achieved in humans by a buccal tablet |
Q47718718 | Potentiated beta-cell response to non-glucose stimuli in insulin-resistant C57BL/6J mice |
Q68899159 | Potentiation of glucose-induced insulin secretion in the perfused rat pancreas by porcine GIP (gastric inhibitory polypeptide), bovine GIP, and bovine GIP(1-39) |
Q51552671 | Prediction of diabetes using ADA or WHO criteria in post-menopausal women: a 10-year follow-up study. |
Q67698313 | Presence of galanin in human pancreatic nerves and inhibition of insulin secretion from isolated human islets |
Q73399802 | Presynaptic sympathetic mechanism in the insulinostatic effect of epinephrine in mouse pancreatic islets |
Q47440507 | Prevention of adhesions by high molecular weight dextran in rats. Re-evaluation in nine experiments |
Q41094685 | Prevention of hyperglycemia improves the long-term result of islet transplantation in streptozotocin-diabetic rats. |
Q40976281 | Protein kinase A inhibition and PACAP-induced insulin secretion in HIT-T15 cells |
Q43869368 | Quantification of insulin secretion in relation to insulin sensitivity in nondiabetic postmenopausal women |
Q72140391 | Quinacrine accumulates in certain peptide hormone-producing cells |
Q42527331 | Quinacrine accumulation in pancreatic islet cells of rat and mouse: relationship to functional activity and effects on basal and stimulated insulin secretion |
Q46124613 | Reappraisal of the intravenous glucose tolerance index for a simple assessment of insulin sensitivity in mice |
Q73374281 | Reclaim the clinical research--proposal to an action plan |
Q46676090 | Reconstructing the pancreas: restoration of normoglycemia, exocrine function, and islet innervation by islet transplantation to the pancreas |
Q73127261 | Reduced GLP-1 and insulin responses and glucose intolerance after gastric glucose in GRP receptor-deleted mice |
Q51574097 | Reduced gastric inhibitory polypeptide but normal glucagon-like peptide 1 response to oral glucose in postmenopausal women with impaired glucose tolerance. |
Q46678800 | Reduced insulin clearance contributes to the increased insulin levels after administration of glucagon-like peptide 1 in mice |
Q38331466 | Reduced pancreatic content of the inhibitory neurotransmitter galanin in genetically obese, hyperinsulinemic mice |
Q90239003 | Reduction in Glycated Hemoglobin and Daily Insulin Dose Alongside Circadian Clock Upregulation in Patients With Type 2 Diabetes Consuming a Three-Meal Diet: A Randomized Clinical Trial |
Q41693076 | Regulation of circulating leptin in humans |
Q51562839 | Relative hyperproinsulinemia as a sign of islet dysfunction in women with impaired glucose tolerance. |
Q40186815 | Release of cyclic AMP from thyroid cells in vitro |
Q69645647 | Repeated hepatic ischemia as a treatment for carcinoid liver metastases |
Q30832022 | Role of VIP and PACAP in islet function |
Q70749975 | Role of extracellular Na+ on CCK-8-induced insulin secretion |
Q34997064 | Role of islet amyloid in type 2 diabetes mellitus: consequence or cause? |
Q37348473 | Role of pituitary adenylate cyclase-activating polypeptide in the pancreatic endocrine system |
Q69740180 | Secretin potentiates cholinergically induced glucagon secretion in the mouse |
Q33518270 | Secretion and dipeptidyl peptidase-4-mediated metabolism of incretin hormones after a mixed meal or glucose ingestion in obese compared to lean, nondiabetic men. |
Q69055115 | Selective alpha 2-adrenoceptor activation by clonidine: effects on 45Ca2+ efflux and insulin secretion from isolated rat islets |
Q88688834 | Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials |
Q45284220 | Sensory nerve desensitization by resiniferatoxin improves glucose tolerance and increases insulin secretion in Zucker Diabetic Fatty rats and is associated with reduced plasma activity of dipeptidyl peptidase IV. |
Q46481403 | Sensory nerve inactivation by resiniferatoxin improves insulin sensitivity in male obese Zucker rats |
Q33196495 | Sensory nerves contribute to insulin secretion by glucagon-like peptide-1 in mice |
Q57675752 | Serum but not cerebrospinal fluid levels of insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 (IGFBP-3) are increased in Alzheimer's disease |
Q43907217 | Serum cholesteryl fatty acid composition and plasma glucose concentrations in Amerindian women |
Q46246161 | Serum uric acid in traditional Pacific Islanders and in Swedes |
Q46333714 | Sex-related differences in the associations between hyperleptinemia, insulin resistance and dysfibrinolysis |
Q39535313 | Shifting the paradigm of islet inflammation--good guy or bad guy? |
Q51578383 | Short-term dexamethasone treatment increases plasma leptin independently of changes in insulin sensitivity in healthy women. |
Q41188277 | Signaling mechanisms underlying the insulinotropic effect of pituitary adenylate cyclase-activating polypeptide in HIT-T15 cells |
Q67285290 | Single injection of terbutaline in term labor: placental transfer and effects on maternal and fetal carbohydrate metabolism |
Q42440190 | Sitagliptin and pioglitazone provide complementary effects on postprandial glucose and pancreatic islet cell function |
Q73548806 | Smoking habits and circulating leptin in postmenopausal non-obese women |
Q39309820 | Somatostatin inhibits thyroid hormone secretion induced by exogenous TSH in man |
Q70941516 | Stimulation of endocrine, but not exocrine, pancreatic secretion during 2-deoxy-D-glucose-induced neuroglycopenia in the conscious pig |
Q34239151 | Stimulation of peripheral T3 formation by oral but not by intravenous glucose administration in fasted subjects |
Q71902529 | Stimulation of somatostatin secretion by 3-O-methylglucose in the perfused dog pancreas |
Q67713791 | Studies on the mechanism by which galanin inhibits insulin secretion in islets |
Q71797626 | Studies on the mechanisms by which gastrin releasing peptide potentiates glucose-induced insulin secretion from mouse islets |
Q33722778 | Study on administration of 1,5-anhydro-D-fructose in C57BL/6J mice challenged with high-fat diet |
Q36711962 | Subtotal pancreatectomy for cancer: closure of the pancreatic remnant with staplers |
Q68665671 | Subtotal pancreatectomy with stapling the pancreatic remnant |
Q38315285 | Suppression of apolipoprotein M expression and secretion in alloxan-diabetic mouse: Partial reversal by insulin |
Q43487999 | Surgical treatment of pancreatic cancer. The Swedish experience |
Q51321546 | Surrogate measures of insulin sensitivity vs the hyperinsulinaemic-euglycaemic clamp: a meta-analysis. |
Q61774856 | Surrogate measures of insulin sensitivity vs the hyperinsulinaemic–euglycaemic clamp: a meta-analysis. Are there not some surrogate indexes lost in this story? Reply to Bastard JP, Rabasa-Lhoret R, Laville M and Disse E [letter] |
Q45173103 | Survivors of childhood acute lymphoblastic leukaemia, with radiation-induced GH deficiency, exhibit hyperleptinaemia and impaired insulin sensitivity, unaffected by 12 months of GH treatment |
Q42498750 | Switching from high-fat to low-fat diet normalizes glucose metabolism and improves glucose-stimulated insulin secretion and insulin sensitivity but not body weight in C57BL/6J mice |
Q68161208 | Sympathetic nerve stimulation versus pancreatic norepinephrine infusion in the dog: 1). Effects on basal release of insulin and glucagon |
Q69900988 | Sympathetic nerve stimulation versus pancreatic norepinephrine infusion in the dog: 2). Effects on basal release of somatostatin and pancreatic polypeptide |
Q51328388 | Synergism by individual macronutrients explains the marked early GLP-1 and islet hormone responses to mixed meal challenge in mice. |
Q72409787 | Temperature-dependent phospholipid degradation in the rat liver during preservation for transplantation. A comparison between different preservation solutions |
Q51773944 | Temporal and dietary fat content-dependent islet adaptation to high-fat feeding-induced glucose intolerance in mice. |
Q89498811 | The Incretin Effect in Female Mice With Double Deletion of GLP-1 and GIP Receptors |
Q68229409 | The Intestinal Peptide PEC-60 Inhibits Insulin Secretion in the Mouse and the Rat |
Q88312476 | The Vildagliptin Experience - 25 Years Since the Initiation of the Novartis Glucagon-like Peptide-1 Based Therapy Programme and 10 Years Since the First Vildagliptin Registration |
Q28257815 | The apj receptor is expressed in pancreatic islets and its ligand, apelin, inhibits insulin secretion in mice |
Q44111025 | The association between leptin and proinsulin is lost with central obesity |
Q46677441 | The augmenting effect on insulin secretion by oral versus intravenous glucose is exaggerated by high-fat diet in mice |
Q33697322 | The canine sympathetic neuropeptide galanin: a neurotransmitter in pancreas, a neuromodulator in liver |
Q43596007 | The cephalic insulin response to meal ingestion in humans is dependent on both cholinergic and noncholinergic mechanisms and is important for postprandial glycemia |
Q73492486 | The cyclic AMP-protein kinase A pathway restrains islet phospholipase A(2) activation |
Q83540652 | The dynamic incretin adaptation and type 2 diabetes |
Q71741934 | The effect of cholecystokinin on proinsulin gene expression in isolated mouse pancreatic islets |
Q67830219 | The effect of pancreatic islets on transplanted hepatocytes in the treatment of acute liver failure in rats |
Q73476399 | The effects of PACAP on insulin secretion and glucose disposal are altered by adrenalectomy in mice |
Q69924694 | The effects of epinephrine on islet hormone secretion in the dog |
Q67923348 | The function of a colloid in liver cold-storage preservation |
Q57113924 | The functional effects of suppression of hypothermia-induced cell swelling in liver preservation by cold storage |
Q31131756 | The high-fat diet-fed mouse: a model for studying mechanisms and treatment of impaired glucose tolerance and type 2 diabetes |
Q84886846 | The hyperstimulated β-cell: prelude to diabetes? |
Q79614917 | The impact of large tidal volume ventilation on the absorption of inhaled insulin in rabbits |
Q73008426 | The influence of potato fibre on exocrine pancreatic secretions and on plasma levels of insulin, secretin and cholecystokinin in growing pigs |
Q33236116 | The insulin response to gastric glucose is reduced in PAC1 and GRP receptor gene deleted mice |
Q37082836 | The islet enhancer vildagliptin: mechanisms of improved glucose metabolism |
Q40501404 | The major glucagon-like peptide-1 metabolite, GLP-1-(9-36)-amide, does not affect glucose or insulin levels in mice |
Q68860966 | The mechanism of vagal nerve stimulation of glucagon and insulin secretion in the dog |
Q85304394 | The neuro-incretin concept |
Q34346667 | The neuropeptide pituitary adenylate cyclase-activating polypeptide and islet function |
Q67537121 | The novel high-affinity antagonist, galantide, blocks the galanin-mediated inhibition of glucose-induced insulin secretion |
Q42078964 | The presence and actions of NPY in the canine endocrine pancreas |
Q73143729 | The relationship between leptin and the insulin resistance syndrome is disturbed in type 2 diabetic subjects with parasympathetic neuropathy |
Q42467771 | Three-day enteral exposure to a red kidney bean lectin preparation enhances the pancreatic response to CCK stimulation in suckling pigs |
Q38690890 | Three-year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: Long-term efficacy with or without rescue therapy |
Q71603608 | Tissue-specific reduction of galanin content in the pancreas in alloxan diabetes in the mouse |
Q80581370 | Traditional versus agricultural lifestyle among Shuar women of the Ecuadorian Amazon: effects on leptin levels |
Q50855262 | Transgenic overexpression of human islet amyloid polypeptide inhibits insulin secretion and glucose elimination after gastric glucose gavage in mice |
Q41917750 | Treatment of pancreatic fistula with the somatostatin analogue SMS 201-995. |
Q33209301 | Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes |
Q46795693 | Two breakthroughs in the treatment of type 2 diabetes. Both the receptor agonist and enzyme inhibitors now available in the clinic |
Q37857686 | Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin |
Q59054209 | VIP occurs in intrathyroidal nerves and stimulates thyroid hormone secretion |
Q70500881 | VIP-stimulated thyroid hormone secretion: effects of other neuropeptides and alpha- or beta-adrenoceptor blockade |
Q45129958 | VPAC2-R mediates the lipolytic effects of pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide in primary rat adipocytes |
Q51741479 | Variables associated with HbA1c and weight reductions when adding liraglutide to multiple daily insulin injections in persons with type 2 diabetes (MDI Liraglutide trial 3). |
Q42962663 | Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study |
Q46143605 | Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes |
Q34362258 | Vildagliptin reduces glucagon during hyperglycemia and sustains glucagon counterregulation during hypoglycemia in type 1 diabetes |
Q33237060 | Vildagliptin: an inhibitor of dipeptidyl peptidase-4 with antidiabetic properties |
Q79152966 | [Clinical research must be based on teaming physician and researcher] |
Q53980330 | [Diabetes and the driving license. Studies of insulin and C-peptide levels] |
Q67259014 | [Glycosylated hemoglobin and control of diabetes] |
Q69631391 | [Ischemic treatment of cancer--a break-through?] |
Q71481599 | [The "diabetes" nurse can manage the classification of metabolic control better than the patient] |
Q84636575 | [Warning against uncritical use of overweight surgery in type 2 diabetes] |
Q84689763 | β-Cell research - A decade of rapid growth |
Q5544511 | Per-Olov Ahrén | child | P40 |
Bo Ahrén | wikipedia |
Search more.